201 related articles for article (PubMed ID: 35696014)
1. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK
Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.
Zhou Q; Liu X; Li J; Tong B; Xu Y; Chen M; Liu X; Gao X; Shi Y; Zhao J; Zhong W; Wang M
Thorac Cancer; 2023 Feb; 14(5):470-478. PubMed ID: 36630992
[TBL] [Abstract][Full Text] [Related]
4. Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab.
Spiliotaki M; Neophytou CM; Vogazianos P; Stylianou I; Gregoriou G; Constantinou AI; Deltas C; Charalambous H
Mol Oncol; 2023 May; 17(5):792-809. PubMed ID: 36177552
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
6. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Dall'Olio FG; Gelsomino F; Conci N; Marcolin L; De Giglio A; Grilli G; Sperandi F; Fontana F; Terracciano M; Fragomeno B; Tober N; Manferrari G; Brocchi S; Golfieri R; Fiorentino M; Ardizzoni A
Clin Lung Cancer; 2021 Sep; 22(5):423-431. PubMed ID: 33849808
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
[TBL] [Abstract][Full Text] [Related]
9. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
[TBL] [Abstract][Full Text] [Related]
10. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Kloten V; Lampignano R; Krahn T; Schlange T
Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of Circulating Tumor Cell PD-L1 Expression and the Association with Clinical Outcomes in Non-Small Cell Lung Cancer.
Acheampong E; Allsopp RC; Page K; Wadsley MK; Beasley AB; Coombes RC; Shaw JA; Gray ES
Clin Chem; 2024 Jan; 70(1):234-249. PubMed ID: 38175603
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.
Tamminga M; de Wit S; Hiltermann TJN; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
J Immunother Cancer; 2019 Jul; 7(1):173. PubMed ID: 31291995
[TBL] [Abstract][Full Text] [Related]
17. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M
Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757
[TBL] [Abstract][Full Text] [Related]
18. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Khattak MA; Reid A; Freeman J; Pereira M; McEvoy A; Lo J; Frank MH; Meniawy T; Didan A; Spencer I; Amanuel B; Millward M; Ziman M; Gray E
Oncologist; 2020 Mar; 25(3):e520-e527. PubMed ID: 32162809
[TBL] [Abstract][Full Text] [Related]
20. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Kim H; Lim DH; Kwon YS; Kim MA; Park KU
Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
